Compile Data Set for Download or QSAR
Report error Found 20 Enz. Inhib. hit(s) with all data for entry = 1807
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341151(US9765058, Example 2-1-1 | 4-({2-[4-chloro-5-cyclo...)
Affinity DataIC50: 4.70nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341153(US9765058, Example 2-2-1 | 2-[4-chloro-5-cycloprop...)
Affinity DataIC50: 5.60nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341168(US9765058, Example 2-4-3)
Affinity DataIC50: 7.40nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341152(US9765058, Example 2-1-2)
Affinity DataIC50: 8.10nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341155(US9765058, Example 2-2-3)
Affinity DataIC50: 10nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341169(US9765058, Example 2-4-4)
Affinity DataIC50: 10nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341170(US9765058, Example 2-4-5)
Affinity DataIC50: 11nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341164(US9765058, Example 2-3-1 | Preparation of 4-({2-[4...)
Affinity DataIC50: 11nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341162(US9765058, Example 2-2-11)
Affinity DataIC50: 13nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341165(US9765058, Example 2-3-2 | US9765058, Example 2-4-...)
Affinity DataIC50: 13nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341165(US9765058, Example 2-3-2 | US9765058, Example 2-4-...)
Affinity DataIC50: 18nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341156(US9765058, Example 2-2-4)
Affinity DataIC50: 24nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341157(US9765058, Example 2-2-5)
Affinity DataIC50: 33nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341154(US9765058, Example 2-2-2)
Affinity DataIC50: 37nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341160(US9765058, Example 2-2-9)
Affinity DataIC50: 40nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341158(US9765058, Example 2-2-6)
Affinity DataIC50: 41nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341166(US9765058, Example 2-4-1 | Preparation of 4-({2-[4...)
Affinity DataIC50: 54nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341163(US9765058, Example 2-2-12)
Affinity DataIC50: 100nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341161(US9765058, Example 2-2-10)
Affinity DataIC50: 250nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341159(US9765058, Example 2-2-8)
Affinity DataIC50: 3.20E+3nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent